Nine ventilated low birthweight babies were treated with dexamethasone (0-6 mg/kg/day). Appreciable suppression of weight gain was accompanied by uraemia and significant increases in the concentration of ali amino acids except phenylalanine, tyrosine, threonine, and glutamate. Ornithine, citrulline, alanine, glutamine, and cystine concentrations increased threefold or more. The findings could not be explained by changes in dietary intake and presumably reflect pronounced catabolism, though the effects of dexamethasone on, intermediary metabolism and membrane transport could also play a part.
The infants studied had been mechanically ventilated from birth. Table 1 gives the birth weight and gestational and postnatal age of each'. Dexamethasone was used in the presence of radiographic abnormalities suggestive of chronic lung disease when conventional respirator weaning techniques had failed. The decision to treat was taken by the clinician responsible and no other experimental intervention to the standard nursery protocol was made. The dose of dexamethasone employed was 0-6 mg/kg/day in three divided doses given intravenously or orally.
FEEDING
The method of feeding was determined by each infant's clinical state and not regulated for the purpose of this study. None of the infants was completely enterally fed and all were receiving commercial parenteral nutrition solutions (Vamin Infant, Kabi Pharmacia, 10% dextrose ±20% Intralipid, Kabi Pharmacia), as a part or the whole of their nutrient intake. The parenteral nutrition regimens used in our nursery provide between 167 and 502 kJ/kg/day, depending on lipid tolerance, and amino acid intake is adjusted to constrain protein equivalent: energy ratio between 3-35 and 6-70 g/MJ. Enterally fed infants received low birthweight formula (Cow and Gate) or human milk when available. Total nitrogen and energy intakes were calculated from nursing records and manufacturers' compositional data. The nitrogen content of human milk was assumed to be 200 mg/100 ml, and the energy content 251 kJ/100 ml or 293 kJ/100 ml, depending on whether banked milk (a mixture of dripped and expressed milk) or mother's own milk respectively was used. ANTHROPOMETRY Weight (g) was measured daily when clinical state permitted, using an averaging electronic scale with resolution of 1 g and precision of ±4 g. Weight gain was calculated as the linear regression coefficient (slope) of these measurements on time (days). This was divided by body weight at the commencement of treatment for comparative expression in units of g/kg/day. Although such ratio 'correction' can lead to erroneous conclusions when comparison is made between infants of differing size, we made comparison only within subjects between treatment periods.
BIOCHEMICAL ANALYSIS
Heparinised venous blood samples (0-5 ml) were drawn before the first dose of dexamethasone and on one occasion between two and seven days later when a clinical indication 1  1041  29  16  2  664  24  32  3  2300  32  13  4  842  28  18  5  726  24  22  6  830  25  45  7  1048  26  31  8 Plasma urea was determined by the urease method on a random access analyser in the hospital routine laboratory.
STATISTICAL ANALYSIS
The number of patients studied was small (n=9) and most variables did not appear normally distributed. Consequently the Wilcoxon signed rank test has been employed to make comparisons before and during treatment within infants. Two tailed probability estimates (p) are quoted throughout; values of <0 05 were deemed significant. Table 2 shows the average daily nitrogen and energy intake of each baby during the seven days before and the seven days after dexamethasone was commenced. These, and protein:energy ratio, did not differ significantly between the two periods (Wilcoxon signed rank test). There was a small difference in the ratio of enteral to parenteral intake between treatment periods: the median proportion of total fluid intake as milk before treatment was 26% (range 0-91%) and 19% (range 0-66%) during treatment. This difference was not significant (Wilcoxon signed rank test, p>0. 1) and was attributable to interruption of enteral feeding on endotracheal extubation.
Results

NITROGEN AND ENERGY INTAKE DURING STUDY
WEIGHT GAIN Figure 1 shows tied values for average daily weight gain or loss during the week before and the week after commencing dexamethasone treatment. In one case insufficient weight data were obtained during the second week to calculate rate of change. In six of the remaining eight cases there was a net weight loss on treatment. These changes were significant (Wilcoxon signed rank test, p<005).
PLASMA UREA CONCENTRATIONS Figure 2 shows the distribution of plasma urea values with time. There was a clear increase in Figure 2 Plasma urea values (mmol/l) during the week before commencing dexamethasone and during thefirst week oftreatment.
both the median plasma urea concentration and variability between individuals during treatment.
PLASMA AMINO ACID CONCENTRATIONS cystine which we measured were lower, and those of methionine, proline, glutamine, and taurine similar to those described by Raiha et al.
The low cystine concentration measured in our study is particularly noteworthy and probably reflects the relatively high requirement for parenteral nutrition and low intake of human milk. The effect ofcorticosteroids on skeletal muscle has also been extensively studied in mature dogs. Muhlbacher et al showed a significant efflux of glutamine from skeletal muscle in animals given 044 mg/kg/day of dexamethasone. 14 However, the changes which they observed in plasma amino acid concentrations differ from those which we have noted in immature infants. Most notably, ornithine, glutamine, and cystine concentrations fell while alanine increased by a factor of only 15. In contrast, rats treated with 6 mg/kg/day of dexamethasone showed a rise in plasma glutamine concentration accompanied by efflux of glutamine and alanine from the lung.'5 This is of interest because the human and the rat, unlike the dog and other species studied, appear to release glutamine from the lung.15 A recent observation that dexamethasone treatment appreciably suppresses lung growth and protein synthesis in the adolescent rat16 raises the possibility that the increased plasma alanine and glutamine concentrations we describe here could be attributable as much to suppression of protein synthesis in the lung as in skeletal muscle. By analogy with the effects of dietary protein restriction in the rat this might be expected to increase lung compliance'7 and produce short term clinical improvement, but also to slow the rate of repair.
In summary, we observed striking increases in the plasma concentrations of most amino acids in immature infants treated with dexamethasone. These changes may reflect suppression of protein synthesis in both the lung and the respiratory musculature, but the relative contributions of effects of membrane transport and intermediary metabolism remain to be determined. 
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